The EPS miss and rising cash burn without revenue create near-term pressure, but the FDA-aligned RESTORE study initiation in mid-2026 is the primary catalyst. Monitor Q2 2026 for CONNECT SCI biomechanical gait analysis results and any financing announcements to extend runway beyond late 2026.
Price Chart
Executive Summary
NervGen Pharma reported Q1 2026 net loss of $1.7M ($0.09 diluted EPS) vs consensus $-0.07, a 28.6% miss on the Street-quoted metric. The company highlighted FDA alignment on its RESTORE registrational study for NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Cash and investments of $16.6M provide runway into late 2026, but the EPS miss and lack of revenue reinforce the pre-commercial, high-burn clinical-stage profile.
Key Financial Metrics
Key Facts
- Q1 2026 diluted EPS of $-0.09 vs consensus $-0.07 (28.6% miss on Street-convention EPS)
- Net loss of $1.7M improved from $3.9M in Q1 2025, driven by $5.7M non-cash unrealized gain on warrant derivative
- Cash and investments of $16.6M as of March 31, 2026
- FDA End-of-Phase 2 meeting completed; RESTORE registrational study on track for mid-2026 initiation
- Biomechanical gait analysis results from CONNECT SCI study expected in Q2 2026
- R&D expenses rose to $4.9M from $3.1M YoY, reflecting preparation for RESTORE study
- Three senior leadership appointments to support late-stage development and Nasdaq listing
Financial Impact
EPS miss of 28.6% on Street-convention diluted EPS; cash burn rate ~$7.6M/quarter (R&D + G&A) implies ~6-7 quarters of runway
Risk Factors
- Cash runway of $16.6M may require dilutive financing before RESTORE data readout
- Clinical-stage biotech with no approved products or revenue; binary risk on RESTORE study outcomes
- EPS miss of 28.6% on Street-convention metric signals operational underperformance vs expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296505 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.42 (+24.47%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.42 (−24.47%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.42 (−29.70%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.32%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.42 (+33.02%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.42 (+29.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.42 (−31.40%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.42 (−31.40%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.42 (+33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers